Orgenesis Inc. Common Stock
ORGS
ORGS was delisted on the 18th of October, 2024.
19 hedge funds and large institutions have $3.02M invested in Orgenesis Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
32% more capital invested
Capital invested by funds: $2.28M → $3.02M (+$741K)
0.23% less ownership
Funds ownership: 6.29% → 6.06% (-0.23%)
14% less funds holding
Funds holding: 22 → 19 (-3)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
80% less call options, than puts
Call options by funds: $1K | Put options by funds: $5K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$26.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.2K |
| 3 |
Prudential Financial
Newark,
New Jersey
|
+$9.54K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.97K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.58K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$42K |
| 2 |
Renaissance Technologies
New York
|
-$5.96K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$494 |
| 4 |
Morgan Stanley
New York
|
-$477 |
| 5 |
Barclays
London,
United Kingdom
|
-$34 |
ORGS Hedge Fund Activity: Q4 2022 in Review
19 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Orgenesis Inc. Common Stock (ORGS) for Q4 2022, worth a combined $3.02M — up 32% from $2.28M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ORGS and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $26.1K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $42K sold.
- 19 institutional investors held Orgenesis Inc. Common Stock (ORGS) as of Q4 2022, down from 22 in Q3 2022.
- Funds reported $3.02M of Orgenesis Inc. Common Stock stock for Q4 2022, up 32% quarter-over-quarter.
- 2 funds opened new Orgenesis Inc. Common Stock positions in Q4 2022 and 3 closed out, a net change of -1 holder.
- The largest Orgenesis Inc. Common Stock buyer in Q4 2022 was Citadel Advisors, an estimated $26.1K added.
- The largest Orgenesis Inc. Common Stock seller in Q4 2022 was Susquehanna International Group, an estimated $42K sold.
Based on aggregated 13F filings for Q4 2022.